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Abstract
The molecular mechanisms involved in tumor pro-
gression from a low-grade astrocytoma to the most
malignant glioblastoma multiforme (GBM) have been
hampered due to lack of suitable experimental models.
We have established a model of tumor progression
comprising of two cell lines derived from the same
astrocytoma tumor with a set of features correspond-
ing to low-grade glioma (as in HNGC-1) and high-grade
GBM (as in HNGC-2). The HNGC-1 cell line is slow-
growing, contact-inhibited, nontumorigenic, and non-
invasive, whereas HNGC-2 is a rapidly proliferating,
anchorage-independent, highly tumorigenic, and in-
vasive cell line. The proliferation of cell lines is
independent of the addition of exogenous growth
factors. Interestingly, the HNGC-2 cell line displays a
near-haploid karyotype except for a disomy of chro-
mosome 2. The two cell lines express the neuronal
precursor and progenitor markers vimentin, nestin,
MAP-2, and NFP160, as well as glial differentiation
protein S100B. The HNGC-1 cell line also expresses
markers of mature neurons like Tuj1 and GFAP, an
astrocytic differentiation marker, hence contributing
toward a more morphologically differentiated pheno-
type with a propensity for neural differentiation in
vitro. Additionally, overexpression of epidermal
growth factor receptor and c-erbB2, and loss of
fibronectin were observed only in the HNGC-2 cell
line, implicating the significance of these pathways in
tumor progression. This in vitro model system
assumes importance in unraveling the cellular and
molecular mechanisms in differentiation, transforma-
tion, and gliomagenesis.
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Introduction
Gliomas are the most common of primary brain tumors and
account for more than 40% of all central nervous system
(CNS) neoplasms. The tumors are thought to arise by the
transformation of an intraparenchymal glial cell that eventually
invades surrounding tissues and develops as a result of
stepwise accumulation of multiple genetic alterations [1,2].
An understanding of the mechanism(s) of tumor progression
from grade 1 anaplastic astrocytoma (AA) to grade 4 glioblas-
toma multiforme (GBM) using a series of experimental
approaches would be of importance in limiting the advance-
ment of the disease and in prolonging survival. Models used to
understand the sequential events leading to malignancy are the
implantation of malignant cells into animal brain tissues and the
creation of a situation similar to tumor growth in vivo. However,
the complexity of such animal models makes it difficult to
identify the individual processes involved in sustained tumor
growth, angiogenesis, and invasion [3]. Other strategies in-
volve using primary cultures of normal human astrocytes trans-
fected with specific gene constructs for studying tumor
progression. Such studies have highlighted the role of p53,
p16/pRB pathway, Ras, and telomerase in AA [4–6]. Activation
of Akt pathway [7], epidermal growth factor receptor (EGFR)
overexpression [5], and upregulation of VEGF [8] individually or
in combination may also be essential to convert AA to GBM.
However, these strategies, besides depending on the success
of establishment of individual primary astrocyte cultures, would
allow the investigator to study only specific pathways triggered
by the gene construct, whereas in most tumors, multiple
oncogenic events cumulatively are required to predispose the
cells toward a completely transformed phenotype. The avail-
ability of different cell lines representing different grades from
AA to GBM transformation independently and yet sequentially
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may form a good model for tumor progression and help in
delineating the exact steps in neoplastic transformation.
Cell lines developed from human CNS tumors are difficult
to establish in long-term cultures and frequently demonstrate
dwindled growth after 10 to 15 passages and reach crisis.
The success rate for establishment of long-term cultures [9]
is as low as 5%, whereas for short-term cultures, it is only
about 41% [10], thus limiting the usefulness of cell cultures
as experimental models. The molecular events leading to
glial neoplasms may result from dedifferentiation of mature
cells or blockage of differentiation in adult glial progenitors
[11]. However, the lack of information about lineages in-
volved in tissue development and the specific precursor cell
population representing normal counterparts of human
tumors and problems encountered in growing CNS tumors
in culture often makes it difficult to delineate the differences
between normal and tumor cells and to understand the steps
involved in gliomagenesis. One of the major issues
addressed regarding the origin of gliomas and other brain
tumors is whether these tumors arise from stem cells or are
derived from adult-differentiated cells, which undergo dedif-
ferentiation and begin to recapitulate development for some
reasons [12]. Recently, Ignatova et al. [13] have reported the
existence of stem-like cells in cortical glial tumors grown in
the presence of pleiotropic factors, which are capable of
developing into clones that are heterogeneous in the expres-
sion of neural lineage-specific proteins. So far, very few
immortalized cells with neural stem cell– like features have
been reported. Among the few well-characterized cell lines is
the mouse hypothalamic cell line (VI) derived from embry-
onic day 14 cells generated using retroviral SV40 constructs
expressing most neuronal and glial markers such as NFPs,
GFAP, and S-100 [14]. Another cell line, the mes-c-myc cell
line (A1), generated by retroviral infection of cultured embry-
onic mesencephalic cells [15], was shown to coexpress both
neuronal and glial markers. However, there are no immor-
talized human cell lines that display both glial and neural
precursor markers.
Here, we report the establishment of a novel model system
generated from human malignant glioma comprising two cell
lines—human neural glial cell lines HNGC-1 and HNGC-2—
which express neural stem cell– like characters. Interestingly,
the HNGC-2 cell line has maintained a stable population of
cells with a near-haploid karyotype for a number of population
doublings in culture. To the best of our knowledge, this model
system comprising of two cell lines with features representing
two sequential stages—grade 1 astrocytoma and grade 4
glioblastoma in gliomagenesis—forms an excellent model
system for studying themechanisms related to transformation
and in furthering knowledge in unraveling the signal trans-
duction pathways in gliomagenesis.
Materials and Methods
Patients
A neuroepithelial tumor diagnosed as glioma was surgi-
cally resected from the frontal lobe of a 66-year-old male at
the Department of Surgery, Government General Hospital
(Pune, India). The tumor tissue was collected in culture
medium after surgery and processed immediately. Informed
consent was sought from the patient. The study was ap-
proved by the Bio-Ethics Committee of NCCS (Pune, India).
Cell Culture
The tumor tissue was washed in Dulbecco’s modified
Eagle’s medium (DMEM) with 10  concentration of peni-
cillin (200 U/ml) and streptomycin (100 U/ml). After three
washes of 10 minutes each with 5  and 1  concentra-
tions of penicillin and streptomycin, the tissue was finely
dissected into 2- to 4-mm tissue fragments. Explant and
adherent cultures were set up with these tissue fragments.
For explant cultures, 10 to 12 explants were seeded ran-
domly in eight 100-mm culture dishes (Falcon, San Jose,
CA) and the plates were left to dry in the laminar hood for 10
to 15 minutes for the explants to adhere to plates. The
explants were then incubated with 100 ml of fetal calf serum
(FCS; Gibco BRL, Carlsbad, CA) at 37jC in a 5% CO2
atmosphere for 5 to 6 hours to promote better attachment
of the explant to the dish. Later, the explants were fed with
DMEM with 10% FCS and incubated at 37jC in 5% CO2
atmosphere and observed daily for outgrowth of cells. On the
second day, cells started emerging from two to three
explants from each dish. Growth from most of the explants
dwindled in 4 to 5 days, but from one of the explants in the
plate, cells grew vigorously and occupied the entire plate by
the tenth day. The cells from this explant were detached
using trypsin phosphate versine glucose (TPVG) and trans-
ferred to new culture dishes (Falcon). The cells from this
primary culture could be propagated further and passaged
continuously up to 25 to 30 generations without any change
in cell morphology, phenotype, and growth characteristics,
and were designated as HNGC-1. Around passage 28, a
clone emerged from these HNGC-1 cells that was morpho-
logically distinct, appeared refractile, displayed piling-up
behavior, and was rapidly proliferating in culture. The clone
was isolated from the HNGC-1 cells using cloning rings,
expanded, and later cloned by limiting dilution. One clone
was selected for study and expanded as a new cell line
HNGC-2. Because HNGC-2 developed from HNGC-1 by
spontaneous transformation of only a small subpopulation
of cells, the HNGC-1 could still be propagated independently
as a cell line. Both cell lines HNGC-1 and HNGC-2 were
cryopreserved at regular intervals and constituted a reper-
toire for further study during their continuous propagation.
The characterization of cell lines was done between pas-
sages 12 and 20 for HNGC-1 and passages between 120
and 130 for HNGC-2 when otherwise stated. Cell prolifera-
tion in the two cell lines was determined by 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyl-tertrazdium bromide (MTT)
assay for different periods up to 96 hours [16].
DNA Content Analysis and Karyotyping
Adequate representative metaphase spreads of good
quality could not be prepared from HNGC-1 due to its slow
growth potential. DNA content analysis and karyotyping data
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were generated only with the fast-growing HNGC-2 cell line.
For DNA content analysis, a 24-hour culture of 5  105
HNGC-2 cells around p60 on fixation with ice-cold 70%
ethanol was stained with 40 mg/ml propidium iodide overnight
and the DNA content per cell was estimated by flow cytom-
eter fixed with 488-nm laser FACSVantage (Becton Dick-
inson, San Jose, CA) [17]. Normal human lymphocytes
processed similarly were used as controls for obtaining a
reference diploid standard. Debris filtering was performed by
gating cells on the basis of forward scatter (FSC) and side
scatter (SSC). The degree of DNA content abnormalities was
given according to the DNA index (DI) using peak channel
values in the major peak with normal lymphocytes as refer-
ence. For practical purpose, cell populations with DI > 1.05
were considered hyperdiploid and those with DI < 0.95 were
considered hypodiploid. For karyotyping, the HNGC-2 cells
around passage p60 were harvested following incubation
with 10 ml of 10 mg/ml colcemid (Gibco BRL) for 2 hours. Cells
were then swollen with 0.075 M KCl at 37jC for 20 minutes.
Cells were pelleted and fixed with 1:3 acetone:methanol
fixative. GTG banding was done on 3-day-old slides using
standard protocols as described [18].
Tumorigenicity Assay in Nude Mice
The HNGC-1 and HNGC-2 cultures were examined for
their potential to induce tumors in 2- to 3-week-old athymic
nude mice. Cells (1  106 cells/mouse) were resuspended
in 0.1 ml of phosphate-buffered saline (PBS) and injected
subcutaneously into the flanks of three nude mice for each of
the cell lines HNGC-1 and HNGC-2. The mice were checked
periodically for tumor growth and sacrificed when the tumor
volume reached about 1000mm3 or after 8 weeks, whichever
was earlier. The tumor volume was calculated using the for-
mula: Tumor Volume=4/3p(Mmajor axis / 2  minor axis / 2)3.
Animal experimentation was done in accordance with the
rules and regulations of the animal ethics committee of the
NCCS.
Matrigel Invasion Assay
The Matrigel invasion chambers were used to assess the
metastatic potential of the cell lines HNGC-1 and HNGC-1
under in vitro conditions. The invasion assay was set up in
BD Bio-Coat Matrigel Invasion Chambers with Falcon Cell
Culture Test Inserts (Becton Dickinson) containing an 8-mm
pore size poly(ethylene terephthalate) (PET) membrane with
a thin layer of Matrigel basement membrane matrix essen-
tially following the manufacturer’s instructions. For invasion
assay, control inserts and test inserts were rehydrated for 2
hours in humidified tissue culture medium at 37jC in 5% CO2
atmosphere and placed in wells of 24-well plates. The
HNGC-1 and HNGC-2 cultures were trypsinized, washed,
and resuspended in DMEM. About 5  104 cells in 0.5 ml of
complete DMEM were seeded in the upper compartment of
each well of the test and control inserts for both the HNGC-1
and HNGC-2 cultures. DMEM with 5% FCS served as a
chemoattractant in the lower compartments of both inserts.
The plate was incubated for 22 hours in a humidified tissue
culture incubator at 37jC in 5% CO2 atmosphere. After
incubation, the noninvading cells on the upper surface were
mechanically scrubbed and removed, and the filters were
fixed and stained with Giemsa for 30 minutes and washed
extensively to remove the excess stain. The invaded cells in
10 microscopic fields were counted with a 10  objective.
The assay was done in duplicate and repeated thrice. The
data were expressed as percent invasion through the Matri-
gel matrix and membrane relative to migration through the
control membrane, and were determined as the mean num-
ber of invading cells in test insert / number of cells migrating
through control insert membrane  100.
Immunofluorescence Staining and Confocal Laser
Scanning Microscopy
For immunophenotyping of the HNGC-1 and HNGC-2 cell
lines, the cells were grown on coverslips for 24 hours, fixed
with 3.7% p-formaldehyde for 10 minutes at 4jC, washed
with PBS, permeabilized with 0.1% Triton X-100, and
blocked in PBS containing 1% bovine serum albumin
(BSA). Mouse monoclonal antibodies antihuman nestin
(Chemicon, Temecula, CA), vimentin (Sigma, St. Louis,
MO), Tuj1 (Chemicon), NFP160 (Sigma), GFAP (Sigma),
S100h (Sigma), and fibronectin (Chemicon), and the rabbit
polyclonal antibody MAP2 antibody (Chemicon) were di-
luted 1:100 in PBS with 1% BSA. For the study of c-erbB2
expression, c-erbB2 monoclonal antibody (Roche, Mann-
heim, Germany) at a dilution of 1:100 was added directly to
the fixed cell. The respective first antibodies were applied
overnight at 4jC. Later, the coverslips were extensively
washed in PBS with 0.5% BSA and 0.5% FCS, followed by
addition of the appropriate second antibody. Secondary
antibodies, anti–mouse IgG FITC and anti– rabbit IgG
FITC (DAKO, Glostrup, Denmark), at a dilution of 1:40 in
the same solution as the primary antibody were applied for
1 hour at room temperature. As a control for immunocyto-
chemistry (in order to exclude nonspecific background
staining), isotype control was included for each immunos-
taining. To visualize the nuclei, the cells were then incu-
bated with 4V,6-diamidino-2-phenylindole (DAPI) (Sigma)
for 10 minutes at room temperature before being mounted
with antifade 1,4-diazobicyclo-2,2,2-octanex (DABCO) in
mounting medium (Sigma). The coverslips were observed
using a pinhole setting of 100 mm with CFLSM (Carl Zeiss,
Jena, Germany). Images were captured by the CCD-4230
camera coupled with the microscope and processed using
the computer-based programmable image analyzer KS300
(Carl Zeiss).
Western Blot Analyses
The HNGC-2 culture was harvested in PBS, and 5  105
cells were lysed in 100 ml of gel loading buffer, separated
by sodium dodecyl sulfate polyacrylamide gel electropho-
resis on a 10% polyacrylamide gel, and transferred onto
Hybond-C-Extra membrane (Amersham, Buckingham-
shire, UK). Immunodetection was performed using 1:100
dilution of c-erbB2 and EGFR antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) for 3 hours at 4jC. The
immunoblot was incubated with anti–mouse-conjugated
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horseradish peroxidase secondary antibody diluted
(1:1000) and developed by ECL Kit (Amersham).
Flow Cytometry Analyses
The c-erbB2 expression in HNGC-2 culture was quanti-
fied by flow cytometry. The HNGC-2 culture was grown to
confluence for 24 hours and the cells were dislodged using
TPVG treatment to obtain a putative single-cell suspension.
Cell count was adjusted to 1  106 cells/tube with PBS
containing 0.1% BSA and fixed with 2% p-formaldehyde for
5 minutes at 4jC. The cells were washed and incubated for
1 hour at 4jC with 1:100 dilution of c-erbB2 antibody. Later,
cells were washed twice in PBS containing 0.1% BSA and
the pellet was incubated with 1:40 dilution of anti–mouse IgG
FITC for 1 hour. After two to three washes in PBS, flow
cytometric analysis was performed with FACS Vantage
(Becton Dickinson) using 488-nm argon laser. Data were
acquired for 10,000 cells and presented as a histogram
(x = intensity of fluorescence and y = number of cells). The
percent positive cells for c-erbB2 were calculated by com-
parison with percent positive cells in negative controls (iso-
type antibody), which were set at 5% positivity cutoff limit.
RNA Extraction and Reverse Transcription Polymerase
Chain Reaction (RT-PCR) Analyses
The guanidine thiocyanate method was used for extrac-
tion of RNA from HNGC-1 and HNGC-2 cell lines using
standard procedures [19]. The RNA was checked for its
integrity on formaldehyde agarose gel and the RNA sam-
ples were DNAsed using the manufacturer’s instructions.
RT-PCR amplification was performed using the following
gene-specific primers: Tuj1 forward: 5V-GGTGTCAGA-
CACGGTGGTGGAAC-3V and Tuj1 reverse 5V-CCACTC-
CACGAAGTAGCTGCTGTTC-3V. The RNA levels were
normalized with respect to the h-actin expression using
forward 5V-TCTTCCAGCCTTCCTTCC-3V and reverse 5V-
CAGGCAGCTCATAGCTCTTC-3V primers. The products
were analyzed on a 2% agarose gel.
Results
Derivation of HNGC-2 Cell Line by Spontaneous
Transformation of HNGC-1
The cell line referred to as HNGC-1 in the study was
derived from a neuro-epithelial tumor classified as a glioma.
The cell culture was started immediately as an explant
culture after its isolation from the tumor tissue. Out of the
75 to 80 explants set up in 100-mm dishes, in 4 to 5 days, a
total of about six to eight explants showed emergence of
small, tightly packed cells that proliferated rapidly. One of the
explant tissues as shown in Figure 1a possessed a prolifer-
ating patch of cells, which in the next 7 to 8 days filled the
entire Petri plate and developed into a cell line HNGC-1.
During serial passaging of HNGC-1, a rapidly growing clone
arose around passage 28 by spontaneous transformation
that markedly differed morphologically from its parental cell
line. The focus of spontaneously transformed cells on isola-
tion and propagation was subcloned by limiting dilution.
Among the eight clones obtained, one clone was chosen
for the present study and propagated as an independent cell
line HNGC-2. Both cell lines HNGC-1 and HNGC-2 have
been in culture for the last 3 years, with HNGC-1 nearing
about 50 and HNGC-2 nearing about 250 passages.
Morphological Features and In Vitro Growth Kinetics
Phase contrast microscopy revealed distinct changes in
cell morphology between the two cell lines HNGC-1 and
Figure 1. Phase contrast photomicrographs depicting (a) cells emerging from
explant after 5 days in vitro. The cells on serial passaging develop into an
early passage cell line HNGC-1 (b). Most cells appear flat with small soma
and large cytoplasmic extensions. A striking morphological change has
occurred in the HNGC-2 cell line (c) on transformation, wherein cells on
confluency pile up, lack cytoplasmic extensions, and display a small refractive
cell body (c). Original magnification,  10.
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HNGC-2, which remained constant at different passages
during serial passaging and did not vary during the last 3
years that the cell lines were in culture. The HNGC-1 cell line
showed large, flat cells that were slow-growing, contact-
inhibited, and displayed branched cytoplasmic cell exten-
sions (Figure 1b). The HNGC-2 cells emerged initially as a
small island of rapidly growing cells in a background of large,
flat cells of HNGC-1 and were characterized by smaller,
refractile, fast-growing, dense patches of cells that were
noncontact-inhibited and displayed a tendency for piling up
and foci formation (Figure 1c). Whether the morphological
differences seen in culture transcended to their growth
potential was assayed using MTT assay. As shown in Figure
2A, the HNGC-1 cells were slow-growing, with a population
doubling time of 72 hours, compared to HNGC-2 cells, which
were rapidly growing and had a doubling time of about 20 to
22 hours. Expectedly, the growth plots revealed that the
mean growth rate for HNGC-1 was significantly slower than
the mean growth rate for HNGC-2. Because both cell lines
were cultured under identical growth conditions, these data
indicate that the observed changes in growth rates of the two
cell lines were not attributable to general incubation condi-
tions during the experiment. Because Ki67 serves as an
index of the proliferation activity of cells, the proliferation
indices of the two cell lines were assessed by their Ki67
immunoreactivity. As represented in Figure 2B, although >
90% cells were expressing Ki67 in the HNGC-2 cell line, only
50% of the cells were positive in HNGC-1, suggesting that
the morphological differences observed between the two cell
lines are also reflected in their proliferation potential in vitro.
DNA Content and Karyotype Analyses of HNGC-2 Cell line
The low growth rate of HNGC-1 precluded us from
preparing satisfactory chromosome spreads for its karyo-
type analyses as well from using it for ploidy studies. DNA
content analyses of HNGC-2 assayed by flow cytometry
using normal human lymphocytes as control revealed that
64.7% of the cells were haploid with DI < 0.87, and 22.28%
cells were hyperdiploid with DI > 1.3 (Figure 3, a and b).
Cytogenetic analysis of HNGC-2 in two different late
passages revealed identical near-haploid karyotypes indi-
cating that chromosomal changes were stably maintained
in both cell lines in different passages. The haploidy was
detected in almost all metaphases, as shown in Figure 4a.
The most frequent karyotype observed was that of cells
with 23 chromosomes with monosomies at every chromo-
some except chromosome 2, which was disomic. Figure 4b
represents a near-haploid cell in metaphase displaying
complex chromosomal rearrangements. The karyotype
was stably maintained in culture as confirmed by karyotype
analyses done at three different passages. Although the
HNGC-1 cell line was derived from a neuro-epithelial tumor
classified as a glioma, the cells appeared more neuronal-
like and tempted us to speculate whether the original tumor
in question was a neuroglial tumor. The cell lines were
characterized for markers specific for both neuronal and
glial lineages.
Stem Cell–Like Characteristics of the Cell Lines with
Coexpression of Neuronal and Glial Markers
The presence of various markers important in neural
lineage specification was examined in both cell lines
HNGC-1 and HNGC-2. The expression and its localization
were analyzed by immunocytochemistry using confocal mi-
croscopy. To characterize the cellular properties of HNGC-1
and HNGC-2, we performed immunocytochemical experi-
ments using non–cross-reactive antibodies against neural
precursor markers nestin and vimentin, glial markers GFAP
and S100h, neuronal markers NSE, MAP2, and Tuj1, and
neurofilaments. The cell lines HNGC-1 and HNGC 2 showed
high expression of nestin (Figure 5), a neurofilament protein
Figure 2. Cell proliferation determined by MTT assay. (A) Graphical
representation over a period of 96 hours in both cell lines HNGC-1 and
HNGC-2. HNGC-2 is a fast-growing cell line and is in the exponential phase
of growth even at 96 hours; its growth plot is represented by hollow circles.
The growth of HNGC-1 cells is slow and plateaus at 48 hours; its growth plot
is represented by open circles. The growth plot is representative of three
similar experiments done independently at two different passages (HNGC-1,
p8 and p18; and HNGC-2, p50 and p60). (B) Represents the growth potential
of both cell lines assessed by their reactivity to Ki67, a proliferation marker.
Only 50% of the cells stain for Ki67 in the HNGC-1 cell line (a), whereas in the
case of HNGC-2 cell line, almost 80% of cells are Ki67+ (b). A corresponding
phase contrast micrograph of the two cell lines is shown for HNGC-1 in (c)
and for HNGC-2 in (d), respectively. The arrow heads in (c) point toward cells
derived from HNGC-1 that are nonimmunoreactive to Ki67. A similar
percentage of Ki67 positivity is obtained in three independent experiments.
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(NFP) that was previously shown to be one of the most
specific markers of multipotent neural stem cells of the CNS,
and vimentin (Figure 5), a neuroepithelial precursor marker.
Immunofluorescence experiments with nestin antibody
showed a distinct subcellular distribution marked with a
speckled appearance of nestin-positive cells in both cell
lines. Nestin is considered to be a developmental marker of
neural cells that are capable of self-renewal with implications
toward possible roles for nestin-positive cells in brain tumor-
igenesis. The high expression of nestin and vimentin inde-
pendent of the malignant behavior of the cell lines argues
against a recent report that nestin expression augments with
increasing tumor grade. The relationship between nestin and
astrocytic differentiation is complex and primary brain tumors
may arise from CNS progenitor cells and nestin expression is
observed irrespective of the astroglial or neuronal origin of
the tumor.
All cells in the two cell lines were weakly positive for low-
molecular-weight and high molecular weight NFPs NFP-68
and NFP-200, but they were all strongly positive for unphos-
phorylated medium-molecular-weight protein NFP-160 (Fig-
ure 5). Glial marker GFAP was positive in most cells in only
the HNGC-1 cell line with homogeneous staining on the cell
surface including cytoplasmic extensions. The expression of
GFAP was totally absent in the transformed cell line HNGC-2
(Figure 5), suggesting an association between the loss of
expression of GFAP with decreasing differentiation and
increasing malignancy. Interestingly, HNGC-1 was intensely
positive for an astroglial marker S100h (green) and MAP-2
(red), a protein linked to the neuronal cytoskeleton in the
mature CNS, as shown in Figure 4, a and b, respectively.
The expression of both glial and neuronal proteins in the cell
line encouraged us to find out whether the same cells coex-
pressed S100h and MAP-2. Our colocalization studies
revealed expression of both molecules to a single cell
Figure 3. Estimation of ploidy and DNA content of HNGC-2 by flow
cytometric analyses. Normal human lymphocytes were used as reference to
determine the relative fluorescence intensity for 2n population with DI = 1 (A).
The distribution of HNGC-2 population with varying DNA indices with
hypodiploidy and hyperdiploidy is shown in (B).
Figure 4. Karyotype of the HNGC-2 cell line. Karyotype analysis was
generated on screening of about 100 metaphases. (A) Representative
karyotype showing near-haploidy and disomy of chromosome 2. (B) A near-
haploid cell of HNGC-2 in metaphase.
Figure 5. Immunofluorescence with antinestin, antivimentin, anti-NFP160,
and GFAP in the cell lines HNGC-1 (left panel) and HNGC-2 (right panel)
(  63) grown for 48 hours in the presence of serum and visualized using
anti –mouse IgG FITC. All photographs are taken at the same settings of
pinhole and detector gain of 100 m.
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(yellow) (Figure 6A,c). A representative picture with more
number of cells in the insert at a lower magnification of  40
clearly shows that all cells colocalize the neuronal and glial
marker. The high S100h expression was seen in the cyto-
plasm and the perinuclear region of cells, whereas MAP2
staining was prominent in the cytoplasm and cell processes.
A similar staining pattern was observed for the transformed
cell line HNGC-2 (Figure 6B) with individual expression of
S100h marked by green fluorescence (Figure 6B,a), MAP-2
marked by red fluorescence (Figure 6B,b), and their coloc-
alization to a single individual cell resulting in yellow fluores-
cence (Figure 6B,c). The corresponding phase contrast
images of both cell lines HNGC-1 and HNGC-2 are shown
in Figure 6, A,d and B,d, respectively, and indicate the fact
that each cell in the population coexpresses the neuronal
and glial markers in both cell types.
The expression of Tuj1, an early neuronal marker, as
examined by immunostaining was seen in a small percent-
age of cells of the HNGC-1 cell line (Figure 7A,a). An image
of Tuj1 positivity in a single representative cell of HNGC-1
cell line is shown in Figure 7A,c. The staining was remark-
ably detected only in the spindle of mitotic cells and in the
midbody of cells joined at cytokinesis, indicating that neuron-
specific tubulin expression was initiated during or before the
final mitosis of neural progenitors. There was a significant
decrease in immunoreactivity with Tuj1 in HNGC-2, as seen
in Figure 7A,b. The corresponding image of HNGC-2 cells
stained with DAPI is illustrated in Figure 7A,d. Although Tuj1
immunostaining indicates expression only in HNGC1, anal-
yses with Tuj1-specific primers in RT-PCR gave a different
picture. Both cell cultures demonstrated similar expressions
of Tuj1, as shown in Figure 7B.
The more differentiated HNGC-1 and the less differenti-
ated HNGC-2 failed to express structural markers NSE and
Tau characteristic of mature differentiated neurons, and the
oligodendrocyte myelinating antigen specific for cells of the
oligodendrocyte lineage (data not shown). The characteriza-
tion studies indicate that both cell lines express both neuro-
nal and glial markers in a single cell and may possibly harbor
a stem and neural progenitor population in CNS tumors.
The HNGC-2 Cell Line Is Highly Tumorigenic and Invasive
Compared to the Known Established Glioma Cell Lines
The HNGC-2 cell line was derived from HNGC-1 by
spontaneous transformation. The HNGC-2 cells were refrac-
tile and proliferated rapidly and, in contrast to HNGC-1,
exhibited all in vitro correlates of transformation like growth
in low serum and clonogenicity in soft agar, with mean ± SD
being 650 ± 68.6 colonies in 10 days (data not shown). The in
vitro correlates of the transforming potential of the cell lines
were strongly matched by their in vivo attribute of tumor
formation in nude mice. No palpable tumors developed in the
HNGC-1 cell line for a period of up to 8 weeks that the mice
were kept under observation. In contrast, in the HNGC-2 cell
line, tumors developed at the site of injection in all the
injected mice within 3 to 4 days and reached a tumor volume
of 1103 ± 246 mm3 in 9 days (Figure 8a). The high tumor load
on the mouse compelled us to sacrifice the mouse on the
10th day itself. A representative of the tumor in situ is
depicted in Figure 8b. Paralleled with high tumorigenicity,
HNGC-2 cells were also characterized by a higher invasion
capacity as assayed by Matrigel penetration assay. The
ability of cells to migrate through Matrigel is enhanced in
metastatic cells and the degradation of the basement mem-
brane is a critical step in tumor invasion. The HNGC-1 and
HNGC-2 cell lines were assayed for their invasiveness by
determining the percentage of cells that can invade the
control insert and test insert. As shown in Figure 9, a and
b, in the HNGC-1 cell line, only 8% to 10% cells migrated
through the test insert compared to the control insert. In
contrast, in the HNGC-2 cell line, about 80% cells migrated
through the test insert compared to the control insert
(Figure 9, c and d ). The capacity of the HNGC-2 cell line
to form vigorous tumors in a short time of 8 to 9 days and its
high invasiveness have not yet been reported to date for any
of the known and widely used glioma cell lines.
Figure 6. Double immunofluorescence labeling of cells. (A) HNGC-1’s and
(B) HNGC-2’s double immunofluorescence labeled with MAP-2 and S100b
antibodies coexpress neuronal and glial markers and are visualized using
fluoresceinated rhodamine-conjugated anti – rabbit IgG and anti –mouse IgG
FITC. Cells independently immunoreactive for MAP-2 stain red (a) and those
immunoreactive for S100 stain green (b), whereas colocalization of both
molecules MAP-2 and S100 to the single cell resulted in yellow color, as
shown in overlay images (d). Note that all cells are dual positive in case of
HNGC-1 (shown in insert—d) as well as in HNGC-2 (d). Original
magnification,  63. A phase contrast micrograph of cells of HNGC-1 and
HNGC-2 is shown in (c).
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Loss of Fibronectin Expression with Decrease in Astrocytic
Differentiation in the Two Cell Lines
Fibronectin is an important extracellular matrix (ECM)
protein involved in cell–microenvironment interaction. Its
loss is frequently associated with increased invasiveness.
The availability of a model system with cell lines of the same
origin and yet varying drastically in their growth potential
would be important in correlating the existence of fibronectin
with invasion. The changes in fibronectin expression in cells
at different passage levels were analyzed by indirect immu-
nofluorescence assay using antibodies to cytoplasmic fibro-
nectin. Figure 10a represents HNGC-1 passage 8 cells
highly expressing fibronectin as an intense filamentous
network. The same cell line at later passages like at p25
demonstrated a gradual decrease in intensity of fibronectin
Figure 7. Expression of Tuj1 in HNGC-1 and HNGC-2 cell lines. (A) Immunoreactivity to Tuj1 was observed only in HNGC-1 as intense filamentous staining (a) in a
small population of cells. A single cell from HNGC-1 displaying the characteristic expression in the mitotic spindle is shown in (c). There was no immunodetectable
expression of Tuj1 in the HNGC-2 cell line. (b) The nucleolus of the same cells stained with DAPI is represented in (d). Original magnification,  63. (B)
Expression of Tuj1 was analyzed at the RNA level by RT-PCR using Tuj1-specific primers. The RT-PCR products were analyzed on 1% agarose gel stained with
ethidium bromide. Lane 1 corresponds to the molecular weight marker 1 kb. Lanes 2 and 3 show expression of the 540-bp Tuj1 in both cell lines HNGC-1 and
HNGC-2. Lanes 4 and 5 represent b-actin PCR used as RNA loading control for the HNGC-1 and HNGC-2 cell lines, respectively. The RT-PCR products were
confirmed by sequencing of the cDNA products.
Figure 8. In vivo tumorigenicity assay. (a) The nude mice injected with only
the HNGC-2 cell line developed tumors rapidly, as shown in the histogram.
The tumor in situ at day 9 is shown in (b). The tumorigenicity data are
represented as tumor volume ± SD of three independent experiments
performed in replicates with groups of three mice each.
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staining (Figure 10b).There was a total loss in expression of
fibronectin in the HNGC-2 cell line, which developed on
spontaneous transformation around p28. The same pattern
of the loss of fibronectin expression was reproduced on
revival of cryopreserved cells at these passages. Similar
results were obtained with secretory fibronectin also as
confirmed by dot blot analyses (data not shown).
EGFR and c-erbB2 Overexpression May Be One of the
Pathways Responsible for Transformation in HNGC-2
EGFR and the mutant form of EGFR, c-erbB2, are
frequently overexpressed in gliomas and other tumors.
Immunostaining with c-erbB2 antibody demonstrated typical
membranous staining in 30% to 40% of the HNGC2 cells and
almost no expression in the HNGC-1 cell line, as studied by
confocal microscopy (Figure 11, a and b). Forty percent of
cells from the HNGC-2 cell line that were positive for c-erbB2
expression also showed a high mean fluorescence intensity
(MFI), indicating overexpression of c-erbB2 receptors
(Figure 11c). A 170-kDa EGFR protein band was evident in
the HNGC-2 cell line on Western blotting (Figure 11d ). The
expression of c-erbB2 of HNGC-2 at the protein level (Figure
11e) was higher than its EGFR expression as observed from
h-actin loading controls (Figure 11f ).
Discussion
We report here the establishment of two novel human cell
lines, designated as HNGC-1 and HNGC-2, derived from a
single astrocytoma tumor. The HNGC-1 cell line represents a
very slow-growing cell line that was contact-inhibited and did
not under go senescence in vitro, suggesting that cells
emerged from the first crisis in the tumor itself. The cell line
could be cultured continuously, was nontumorigenic, and
represented a premalignant cell line. During serial passaging
of the HNGC-1 cell line, few of the cells overcame the second
proliferative block referred to as crisis and a spontaneously
transformed clone emerged around passage 28. The cell line
established from this clone is referred to as HNGC-2. The
two cell lines HNGC-1 and HNGC-2 differ strikingly in their
morphological appearance, growth characteristics, tumori-
genic potential, as well as invasiveness, and represent a
stable transition in vitro from low-grade astrocytoma (as in
HNGC-1) to high-grade GBM (as in HNGC-2).
The HNGC-2 cell line on cytogenetic analysis demon-
strated an unusual karyotype with near-haploidy and various
structural complex chromosomal translocations. Peculiarly,
this clonogenic cell line remained karyotypically stable over
all passages in culture, allowing for the continuous mainte-
nance of near-haploid cells in culture. There are very few
reports about a stable haploid cell line developed from a solid
tumor although an unusually high percentage of epitheloid
tumors as well as all cases that do show hypodiploidy
correlate with adverse prognosis [20,21]. Haploidization
may possibly be the result of an abnormal karyokinesis
induced in the tumor [22], or due to the multiple genetic
alterations occurring during malignant transformation in cul-
ture. The cause of near-haploidy seen in HNGC-2 is not yet
discernable and needs to be further investigated.
A detailed analysis of molecular markers comprising
neuroepithelial stem and precursor cell markers nestin
and vimentin; early and late neuronal differentiation
markers NFPs, MAP-2, Tuj1; and glial markers S-100h
and GFAP revealed that both cell lines express markers
important in neural lineage specification and differentiation.
Serially passaged cells were uniformly immunoreactive for
lineage-independent early neuroepithelial markers nestin
[23] and vimentin [24]. In few adult neurons and in glial
progenitor cells, vimentin is present along with nestin, and
vimentin along with GFAP are present in mature astrocytes
[24]. Although vimentin, the major cytoskeletal component
present in immature glia [25], is expressed to the same
extent in all grades of astrocytic tumors, the intensity of
nestin immunostaining correlates with the malignancy
grade in gliomas [22,26,27]. The expression of nestin, an
Figure 9. Matrigel invasion assay. For the HNGC-1 (a,b) and HNGC-2 (c,d)
cell lines, cells penetrating through the control insert are shown in (a & c) and
those penetrating through the test insert are shown in (b & d). The data are
representative of one of five independent experiments.
Figure 10. Progressive loss of fibronectin immunoreactivity on malignant
transformation of HNGC-1 cell line. (a) Intense expression of fibronectin in
HNGC-1 cells at p18, (b) with a subsequent diminution in intensity at p28 in
the HNGC-1 cell line (c) and a total loss of expression in the HNGC-2 cell line.
Inset in (c) shows a phase contrast micrograph of HNGC-2 cells. All
photographs were taken at the same settings of pinhole and detector gain.
Original magnification,  63. Similar results were obtained on cells revived
after cryopreservation at the mentioned passages or even in passages close
to the ones mentioned above.
528 Novel Model System for Tumor Progression in Glioblastoma Shiras et al.
Neoplasia . Vol. 5, No. 6, 2003
intermediate filament protein used to describe stem and
progenitor cells, is reported during the transition from a
progenitor stage to glial differentiation in the mammalian
CNS, suggesting a differential temporal regulation of nestin
expression during glial and neuronal cell differentiation
[28]. Contrary to these reports, in our model system, it is
intriguing that the slow-growing, more differentiated HNGC-
1 and highly tumorigenic and invasive HNGC-2 showed
similar high expression of nestin, thereby suggesting a lack
of association between nestin and malignancy. Although
expression of vimentin has been reported in most of the
glioma cell lines U-118MG, U-373MG, Hs683, and U-
87MG, nestin has been reported only in the U-373MG
glioma cell line as a diffused cytoplasmic fluorescence
[27]. An association between nestin expression and as-
cending malignancy has been documented in clinical sam-
ples but does not seem to exist in cell lines. Surprisingly,
nestin was not detected in U-87MG and Hs683 cell lines,
both derived from malignant glioma, suggesting that nestin
expression may not directly correlate with malignancy in
cell lines and argues toward the possibility of a stem/
precursor cell population in the tumor of origin.
GFAP, a protein marker important in astrocytic differen-
tiation, is expressed in astrocytoma cell lines [29]. Our
findings of expression of GFAP in the more differentiated
HNGC-1 and its loss in the transformed HNGC-2 reflect the
in situ clinical picture in the tumors supporting the specula-
tion that loss of GFAP expression may reflect tumor pro-
gression toward a more rapidly growing and malignant
phenotype [30]. Also, the changes in GFAP and nestin gene
expression correlate with changes in shape and motility as
seen with U373 cells, and indicate that these cells have
progressed toward a less differentiated state [31]. The loss of
GFAP in HNGC-2 is possibly responsible in driving it toward
Figure 11. Expression of c-erbB2 and EGFR. The HNGC-1 cell line was not immunopositive for c-erbB2, as assayed by immunostaining with c-erbB2 antibody (A).
About 30% to 40% of the cells from the HNGC-2 cell line showed a strong membranous staining for c-erbB2 (B) and this was quantitatively assayed by flow
cytometry wherein, as demonstrated in a representative experiment, a distinct peak of erbB2+ cells is observed with a percent positivity of 35% and an MFI of 38
above a negative cutoff with isotype control of 5% (C). HNGC-2 expressed a 170-kDa EGFR band in Western blotting (D). The expression of c-erbB2 as a 185-kDa
protein (E) in the HNGC-2 cell line was comparable to that of the A431 cell line used as a positive control. Equal loading of protein was confirmed by using b-actin
loading controls for the two cell lines A431(f) and HNGC-2 .
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a highly transformed state and further exemplifies the use-
fulness of our model system in tumor progression.
The positivity of markers vimentin, nestin, GFAP, and
S100h pointed towards astrocytic lineage of the cell lines.
Because one of the goals of our study was to determine the
contribution of individual cytoskeletal elements during differ-
entiation and malignant transformation, we attempted to
characterize the cell lines for expression of neuronal markers
MAP-2, Tuj-1, and NFPs, and also study the coexpression of
neuronal marker (MAP-2) with an astrocytic marker (S100h)
to the same cell due to the heterogeneity in gliomas.
MAP2, a neuronal marker, has been recently identified in
glial precursor cells, indicating its potential role in glial
development [32]. Although expression of high-molecular-
weight MAP-2 has been reported in high-grade astrocytomas
and oligodendroglial neoplasms [33], its presence in the glial
cell lines is not reported. Coexpression of S100h and MAP-2
was seen in all cells derived from both cell lines HNGC-1 and
HNGC-2, indicating the existence of a neural precursor
population that can undergo morphological and functional
differentiation into neuronal and glial lineage without losing
its precursor properties [15]. The aberrant expression of both
neuronal and glial markers to the same cell type has been
reported in reactive mouse astrocytes treated with EGF
wherein coexpression of neuronal markers like GABA, Tau,
and Map-2 with glial markers GFAP and nestin was ob-
served, suggesting that these cells may have arisen either in
response to CNS trauma, or may have been derived from
neural progenitor cells rather than from previously differen-
tiated astrocytes [34]. Another explanation could be that
although the expression of IF proteins is tissue-specific and
developmentally regulated, and is a good marker for deter-
mining the cell origin and differentiation status of tumor cells,
like GFAP expressed only in astrocytomas and NFPs only in
tumors of neuronal origin, the tumor cells themselves may
express IF patterns, which are irrelevant to the cell origin and
differentiation status of tumors [35].
The neuronal commitment marker, Tuj1, important in the
development and differentiation of CNS [36], was positive in
HNGC-1 and HNGC-2 at the RNA level. Although Tuj1
expression has been observed to the same extent at the
RNA level in both cell lines, it is detectable at the protein level
only in HNGC-1, suggesting that changes in mRNA levels
often precede and are more pronounced than changes in
protein levels. NFP, another marker for neuronal commit-
ment, was intensely expressed in almost all cells in both cell
lines, furthering our conjecture of a neuronal phenotype in
the cell lines under study. Although the expression of neu-
ronal markers nestin MAP-2, Tuj1, and NFP-160 in tumor
specimens from astrocytomas/gliomas is associated with
high-grade malignancy, there are no cell line(s) derived from
astroglial tumors that express MAP2, Tuj1, and NFP-160
proteins. Although there are reports on the coexpression of
nestin, vimentin, and GFAP in the U-373MG glioma cell line
and another report on the coexpression of GFAP, vimentin,
and cytokeratins in the GL-15 glioblastoma cell line, there are
no cell lines reported that coexpress neuroepithelial stem
and progenitor markers as well as mature neural markers. To
the authors’ knowledge, this is the first report on human
glioma/neuroglial cell lines possessing the unique feature of
coexpression of neuronal markers such as nestin, vimentin,
MAP-2, and NFP160, and glial markers S-100h and GFAP.
Except GFAP, as these markers are expressed in both cell
lines to the same extent and have no relation to the tumor-
igenicity of the cell lines, it is tempting to speculate the
possibility of existence of stem cell/precursor cell population
in the derived cell line with a tendency toward neuronal
differentiation.
The HNGC-2 cell line is highly tumorigenic and invasive,
and its tumor-forming potential is remarkably high compared
to the available established glioma cell lines. Most glioma
cell lines A172, H4, Hs683, U-138MG, and U-118MG are
nontumorigenic, although some of these cell lines are
known to form colonies in soft agar. Even the glioma cell
lines U-87MG, LN18, and LN229 derived from aggressive
and malignant tumors require very high cell number (107)
and longer periods up to 2 to 3 months to produce an
appreciable size of tumors in nude/SCID mice. T98G cells
derived from a grade 4 human glioblastoma multiform tumor
does not grow when implanted subcutaneously or intrace-
rebrally in nude mice and forms tumors only when sus-
pended in reconstituted basement membrane Matrigel [37].
In a striking contrast, the HNGC-2 cell line produced large
tumors (> 1000 mm3) within 6 days of injection with only 106
cells when suspended in PBS. Our study with the cell lines
found significant correlation between Ki67 expression and
growth kinetics in vitro and in vivo tumor growth, suggesting
that in vitro changes are related to malignant progression
in vivo [38].
Matrigel penetration assays were used to compare
invasive activities in HNGC-1 and HNGC-2 cell lines. The
HNGC-1 cell line showed low invasion activity (12%),
whereas the HNGC-2 cell line demonstrated a five-fold
greater invasion potential (60%), which is significantly
higher than published values (40%) of the HT 1080 fibro-
sarcoma cell line [39]. Glioma being an aggressive and
invasive tumor, the availability of a highly invasive cell line
will be appropriate for transformation studies. In the pres-
ent study, we found a progressive loss in fibronectin
expression during the evolution of HNGC-2 from HNGC-1.
This reaffirms the usefulness of this model system in
understanding tumor progression as sequential fibronectin
loss would contribute toward a more rapidly growing and
malignant phenotype in HNGC-2.
The high tumorigenicity and transforming potential of
HNGC-2 could also be due to the overexpression of EGFR
and c-erbB-2 oncoproteins. Studies with different grades of
astrocytomas and gliomas revealed no expression of the
EGFR and c-erbB-2 protein in low-grade astrocytomas (G1,
G2) but a remarkable increase in anaplastic and malignant
gliomas [40]. The results emphasized that EGFR and
c-erbB-2 proteins were expressed in astrocytic tumors with
increased malignancy and dedifferentiation.
Frequent genetic alterations in aggressive grade 4 glioma
result in stimulation of common signal transduction pathways
involving oncogenes [41]. According to a recent report,
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EGFR gene amplification demonstrated in GBM cells in vivo
is lost when cells are cultured in vitro during multiple pas-
sages [42]. Interestingly, high levels of EGFR and c-erbB2
were expressed in the HNGC-2 cell line, whereas no detect-
able levels were seen in the HNGC-1 line. However, the high
expression in the HNGC-2 and not in the HNGC-1 cell line
suggests that its expression might be related to malignant
phenotypes of the HNGC-2 on transformation. Although
overexpression of EGFR has been associated with GBM,
there are no appropriate cell lines for understanding EGF
signaling with the only exception of SKMG-3 [43]. Based on
these reports and our findings, we propose that these two
cell lines would be a good model to study mechanisms in
EGF signaling and tumor progression in gliomas.
The pathways in gliomagenesis that lead to malignancy
are multiple and complex, and involve abnormalities in the
cell cycle proteins, p16-cdk4-pRb, cell cycle arrest pathways
involving ARF-MDM2-p53, and deregulation of lipid phos-
phatase PTEN, which regulate cellular responses to receptor
tyrosine kinases [6,44]. The precise molecular event(s)
triggered when overcoming the crisis resulting in neoplastic
transformation and progression in our HNGC-2 cell line
remains unknown. A number of issues that could be
addressed using the two cell lines would be: analysis of the
significance of cytoskeletal elements in neural tumors, un-
derstanding the implications of the coexpression of interme-
diate filament proteins in malignancy, and, ultimately,
deciphering the signaling pathway in tumor progression. In
conclusion, the in vitromodel system developed by us would
be valuable to understanding the contribution of several
genes associated with tumorigenesis, to unraveling the steps
in anaplastic progression in gliomas, and to providing better
therapeutic strategies for patients with malignant
CNS tumors.
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